Humana sues Regeneron over pricing of popular macular degeneration drug

Insurance company Humana filed a racketeering and fraud lawsuit against Regeneron Pharmaceuticals on Thursday over a copay assistance scheme for its top-selling drug, Eylea.

Humana’s suit is based on allegations by the U.S. Department of Justice last year that Regeneron gave a patient-assistance charity kickbacks to boost sales of Eylea, which treats age-related macular degeneration. That case is ongoing in Boston’s federal court.

Humana accused Regeneron of inflating the drug’s price from $1,500 a dose to $1,950 by partnering with the charity, the Chronic Disease Foundation, to cover patients’ cost-sharing obligations for Eylea but not for its competitor. The arrangement boosted Eylea sales at the

Facebook Notice for EU!
You need to login to view and post FB Comments!

→ Continue reading at Crain's New York Business

[ufc-fb-comments url=""]

Latest Articles

Related Articles